anti cldn6 monoclonal antibody asp1650

Drug Overview

The treatment of advanced solid tumors has been significantly advanced by the development of precision-targeted therapy. anti cldn6 monoclonal antibody asp1650 (also known as IMAB027) is a humanized monoclonal antibody designed to identify and attack specific proteins that are found almost exclusively on cancer cells.

This medication targets a protein called Claudin-6 (CLDN6). In a healthy adult body, this protein is usually “silent” and not found in normal tissues. However, certain types of aggressive cancers “turn on” this protein to help the tumor grow and survive. By targeting a protein that is absent in healthy cells, ASP1650 aims to provide a powerful anti-cancer effect while minimizing damage to the rest of the body.

• Generic Name: Anti-CLDN6 Monoclonal Antibody ASP1650
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: Humanized Monoclonal Antibody; Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Phase 1/2 clinical trials)

What Is It and How Does It Work? (Mechanism of Action)

Targeting Claudin-6 (CLDN6)

Claudins are proteins that act like “glue” in the tight junctions between cells. CLDN6 is a unique member of this family because it is an oncofetal antigen. This means it is present during fetal development but disappears before birth. When it reappears in adulthood, it is almost always a marker of malignancy, particularly in germ cell tumors and ovarian cancers.

Molecular Mechanisms

Once ASP1650 is infused into the patient, it seeks out cells expressing CLDN6 and attaches to them. This binding triggers three main destructive pathways:

1. Antibody-Dependent Cellular Cytotoxicity (ADCC): The antibody acts as a bright signal or “flag.” Immune cells, such as Natural Killer (NK) cells, see this flag and are recruited to the tumor site to release toxic chemicals that kill the cancer cell.
2. Complement-Dependent Cytotoxicity (CDC): The binding of ASP1650 activates the “complement system” in the blood. This creates a series of proteins that punch holes in the cancer cell’s membrane, causing it to burst.
3. Inhibition of Signaling: By sitting on the CLDN6 receptor, ASP1650 may block vital growth signals that the tumor needs to replicate and spread (metastasis).

FDA-Approved Clinical Indications

Oncological Uses

ASP1650 is currently an investigational drug and is not yet approved for general sale. It is primarily being studied for:

• Advanced Ovarian Cancer: Specifically for patients who have not responded to platinum-based chemotherapy.
• Testicular Germ Cell Tumors: For patients whose cancer has returned (relapsed) or is resistant to standard treatments.
• Other CLDN6-Positive Solid Tumors: Including certain types of lung and gastric cancers.

Non-Oncological Uses

• There are currently no non-oncological indications for this drug.

Dosage and Administration Protocols

Because ASP1650 is in the clinical trial phase, the exact dosage is determined by the specific study protocol and the patient’s body surface area or weight.

Dose Adjustments

• Renal/Hepatic Insufficiency: Monoclonal antibodies are generally processed by the immune system rather than the liver or kidneys. However, if liver enzymes or kidney function tests show a significant decline, doctors may delay the dose until the organs recover.
• Infusion Reactions: If a patient has a reaction, the infusion is slowed down or stopped, and the dose for the next visit may be adjusted.

Clinical Efficacy and Research Results

Clinical trials conducted between 2020 and 2025 have focused on patients with “heavily pre-treated” cancers, meaning they had already tried and failed many other therapies.

• Disease Control Rate (DCR): In Phase 1/2 studies involving patients with CLDN6-positive ovarian cancer, a significant percentage achieved “Stable Disease,” meaning the tumor stopped growing for a period of time.
• Target Accuracy: Research has confirmed that ASP1650 successfully reaches the tumor tissue. In patients with high levels of CLDN6 expression, the drug showed higher biological activity.
• Safety Data: Numerical data from recent cohorts indicate that the drug is generally well-tolerated at doses up to 1000 mg/m², with very few patients needing to stop treatment due to toxicity.

Safety Profile and Side Effects

ASP1650 is designed to be more targeted than traditional chemotherapy, but it can still cause side effects as the body reacts to the protein infusion.

Common Side Effects (>10%)

• Nausea and Vomiting: Often mild and manageable with standard anti-nausea medicine.
• Fatigue: A general feeling of tiredness or low energy.
• Infusion-Related Reactions: Chills, fever, or flushing during or shortly after the IV drip.
• Decreased Appetite: A temporary loss of interest in food.

Serious Adverse Events

• Anaphylaxis: A rare but severe allergic reaction.
• Hematologic Changes: Potential drops in white blood cell counts, which can increase infection risk.
• Management: Infusion reactions are managed by giving patients “pre-medications” like antihistamines or steroids. If a serious reaction occurs, the infusion is stopped immediately.

Research Areas

Current research is exploring the use of ASP1650 in combination with CAR-T Cell Therapy. Scientists are using ASP1650 to help “prime” the tumor environment, making it easier for engineered immune cells to find and destroy the cancer. Additionally, researchers are investigating whether CLDN6-targeted therapies can be used in Regenerative Medicine contexts to distinguish between healthy pluripotent stem cells and those that have turned into “teratomas” or tumors, ensuring that stem cell therapies remain safe for patients.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• CLDN6 Expression Test: A biopsy of the tumor is required to confirm that it contains the Claudin-6 protein target.
• Blood Panel: Complete blood count (CBC) and metabolic panel to check liver and kidney health.
• Pregnancy Test: Required for women of childbearing age, as the drug’s effect on a fetus is unknown.

Precautions During Treatment

• Monitor for Fever: Patients should report any fever or chills occurring after the infusion.
• Hydration: Maintaining good fluid intake helps the body process the medication.

Do’s and Don’ts

• DO tell your doctor if you have a history of severe allergies to other antibody treatments.
• DO keep track of any new skin rashes or digestive changes.
• DON’T ignore sudden shortness of breath or chest tightness during the infusion.
• DON’T start any new vaccinations without consulting your oncologist, as your immune system is being modulated.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only and is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, oncologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. ASP1650 is an investigational drug available only through clinical trials.